Antibody-drug conjugates, or ADCs, are often described as guided missiles: a monoclonal antibody engineered to recognize a specific surface protein is chemically linked to a potent cytotoxic payload, allowing the drug to deliver its lethal cargo preferentially to cells bearing the target. Three such targets have already demonstrated clinical efficacy in urothelial carcinoma—NECTIN4, TACSTD2 (better known as TROP-2), and ERBB2 (HER2). Yet the authors of the new study noted a conspicuous gap: few investigations had systematically mapped how these targets behave at single-cell resolution in relation to tumor differentiation states, intrinsic biological programs, and the surrounding immune microenvironment. That gap matters, because a target that glows brightly in one region of a tumor may be nearly invisible in another, even within the same patient.

To build their atlas, the team integrated single-cell RNA sequencing data from three public cohorts, applying Harmony batch correction to merge datasets generated in different laboratories without erasing genuine biological differences. Quality-control metrics, benchmarking against an alternative integration method, and copy-number-variation-based validation of malignancy all supported the robustness of the merged dataset. Within the epithelial compartment, the researchers assigned consensus molecular subtype classifications at single-cell resolution, distinguishing basal, luminal, and neuroendocrine-like tumor populations. They then applied pseudotime trajectory inference using the Slingshot algorithm to order tumor cells along a basal-to-luminal differentiation axis, effectively reconstructing a maturation timeline from the static snapshot of sequencing data.

What emerged from that trajectory analysis was a striking divergence in how the three ADC targets are distributed along the differentiation axis. TROP-2, encoded by TACSTD2, was expressed broadly across the entire trajectory, making it the most uniform of the targets—a property reflected in its low inter-patient heterogeneity, with a Gini index of just 0.27 compared with 0.67 for NECTIN4, the most variable target. ERBB2/HER2, by contrast, was sharply localized to a narrow window along the trajectory, and that window coincided with elevated activity of ABC transporter genes—a family of drug efflux pumps with obvious relevance to chemotherapy resistance. NECTIN4 told a third story: it was virtually absent in early basal cells and rose progressively through the partial-epithelial-to-mesenchymal-transition zone, the transitional state that many tumor biologists associate with plasticity and metastatic potential.

These expression patterns were not merely descriptive. Patient-level analyses linked TROP-2 expression to elevated epithelial-mesenchymal transition program activity and HER2 expression to elevated ABC transporter activity, with modest associations to interferon-gamma signaling. The team validated their findings across species, showing that broad TROP-2 expression enriched in more differentiated cells is conserved in normal human and mouse urothelium, suggesting it reflects a fundamental physiological property of urothelial differentiation rather than a tumor-specific quirk. Bootstrap analyses resampling the 21 patients 200 times confirmed that the breadth-versus-focality differences between targets were statistically supported, though the peak positions of NECTIN4 and HER2 along pseudotime could not be cleanly separated from one another.

Perhaps the most provocative result came from the CellChat analysis of tumor-immune communication. The researchers, including a custom-curated ligand-receptor pair, found that NECTIN4-TIGIT ranked as the top predicted tumor-to-immune inhibitory checkpoint interaction, with tumor epithelial cells serving as the exclusive predicted source of NECTIN4-mediated TIGIT engagement. TIGIT is an inhibitory receptor on T cells and natural killer cells, and the finding implies that the very molecule drug developers exploit to shuttle toxins into tumors may simultaneously be helping the cancer suppress the immune cells that ADCs rely on for antibody-dependent cellular cytotoxicity. If confirmed experimentally, this dual role would provide a mechanistic rationale for combining NECTIN4-directed ADCs with TIGIT blockade.

The communication analysis also surfaced an unexpected player: the APP-CD74 axis, in which amyloid precursor protein—a molecule famous for its role in Alzheimer’s disease—emerged as a tumor-derived signal engaging CD74 on immune cells. The researchers detected 26 significant intercellular interactions along this axis, and validation in the TCGA-BLCA bulk transcriptomic cohort of 403 to 412 patients showed that tumors with high APP and low CD74 expression had the worst overall survival, with a hazard ratio of 2.00 (95 percent confidence interval 1.31 to 3.04, p equals 0.001). The authors were careful in their framing: the data suggest that disruption of this axis is associated with worse survival, not that it is causally responsible, but the association was strong enough to flag APP-CD74 as a novel prognostic communication axis worthy of functional follow-up.

The differentiation theme extended to patient outcomes in the TCGA-BLCA validation cohort. When the researchers distilled their pseudotime analysis into a differentiation signature and applied it to bulk tumor data, they found that early-differentiation tumors—those dominated by basal-like cells—carried significantly worse overall survival, with a hazard ratio of 1.58 (95 percent confidence interval 1.12 to 2.24, p equals 0.009), a result that held in multivariate models adjusting for molecular subtype, pathologic stage, and age. These early-differentiation tumors were enriched for epithelial-mesenchymal transition activity (Spearman rho of negative 0.398 with the differentiation index), interferon-gamma response (rho of negative 0.430), and proliferation signatures (rho of negative 0.502). Intriguingly, they also harbored elevated tumor mutational burden, hinting that despite their aggressive biology, these tumors might still respond to immune checkpoint inhibitors—a nuance that could matter for sequencing therapy in the clinic.

For the ADC field, the takeaway is that target expression breadth should inform biomarker-guided stratification. A target like TROP-2, expressed broadly across the differentiation spectrum and consistently across patients, offers a wide therapeutic window in principle; a target like HER2, confined to a narrow differentiation window and coupled to drug-efflux machinery, may require more careful patient selection and combination strategies to overcome resistance. NECTIN4’s dependence on differentiation state helps explain why it is the most heterogeneous target between patients, and why a biopsy from one region of a tumor might substantially overestimate or underestimate the true burden of target-positive cells. The pseudotime-derived differentiation signature, the authors propose, could serve as a biomarker to guide ADC therapy selection in urothelial carcinoma, complementing the molecular subtyping frameworks already in clinical discussion.

The study is not without caveats, several of which the authors acknowledge in their supplementary analyses. The atlas, while among the largest for this disease, derives from 21 patients, and pseudotime inference reconstructs a trajectory that cells may not literally traverse in vivo. The NECTIN4-TIGIT and APP-CD74 findings are computational predictions that will need wet-lab confirmation, and the published version remains subject to final editorial revision. Still, the work exemplifies a broader shift in oncology: from viewing tumors as uniform masses bearing static molecular flags, to reading them as ecosystems in which drug targets, immune evasion programs, and differentiation states are woven together—and in which the most effective therapies will be those designed with that dynamism in mind.

Subject of Research: Single-cell transcriptomic mapping of antibody-drug conjugate target dynamics and tumor-immune checkpoint interactions in muscle-invasive bladder cancer

Article Title: Single-cell transcriptomic profiling of muscle-invasive bladder cancer reveals differentiation-dependent ADC target dynamics and tumor-immune checkpoint interactions

Article References: Chang, P. M.-H., Yen, C.-C., Wu, W.-C., & Lai, J.-I. (2026). Single-cell transcriptomic profiling of muscle-invasive bladder cancer reveals differentiation-dependent ADC target dynamics and tumor-immune checkpoint interactions. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08916-2

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08916-2

Keywords: bladder cancer, single-cell RNA sequencing, antibody-drug conjugates, NECTIN4, TROP-2, HER2, TIGIT, APP-CD74 axis, pseudotime trajectory, tumor microenvironment, biomarkers, urothelial carcinoma

The research team, led by investigators at Nationwide Children’s Hospital and Cincinnati Children’s Hospital Medical Center, began with a resource that few groups possess: autopsy-derived tumor specimens from twenty-six DIPG patients, each paired with matched normal frontal lobe tissue obtained through the Pediatric Brain Tumor Repository under institutional review board-approved protocols with informed consent from families. Bulk RNA sequencing of these paired samples revealed a transcriptome in upheaval. More than two thousand genes were significantly upregulated in tumor tissue, and among them were signatures of immune modulatory factors, including checkpoint genes such as PDCD1 and LAG3 and myeloid-associated genes including CSF1, CD163, CD86, and CCL2. Gene Ontology analysis showed that five of the top enriched pathways involved MHC-mediated antigen presentation, indicating that despite their reputation as immunologically cold tumors, DIPG tissues retain active immunological interfaces.

The apparent paradox, in which antigen presentation machinery is broadly induced while cytotoxic T cells remain scarce, likely reflects a dysfunctional immune interface rather than a functional anti-tumor response. Indeed, when the researchers correlated the expression of macrophage lineage markers such as CD11b, CD14, and STAT6 with patient survival, higher expression of each was significantly associated with shorter survival duration. This finding reinforced a growing consensus that tumor-associated myeloid cells, rather than functioning as anti-tumor sentinels, actively promote disease progression in DIPG. Consistent with earlier work showing sparse lymphocyte infiltration in these tumors, the data painted a portrait of a microenvironment dominated by microglia and monocyte-derived macrophages that have been recruited and shaped by the tumor itself.

To probe how that recruitment happens, the team turned to laboratory experiments with four patient-derived DIPG cell lines and THP-1 human monocytes in transwell migration assays. The results were striking in their asymmetry. SU-DIPG-IV and SU-DIPG-XXXVI, both carrying the H3.1K27M mutation, markedly enhanced monocyte migration and drove the cells toward an immunosuppressive CD11b-positive CD163-positive phenotype, while CCHMC-DIPG-1 and CCHMC-DIPG-2 showed no such capacity. Multiplex cytokine assays revealed that the two potent lines secreted far higher levels of CCL2, IL-10, and TGF-beta1. Yet when the investigators analyzed RNA sequencing data from forty-six pediatric high-grade glioma cell lines in the Childhood Cancer Model Atlas, they found that chemokine expression did not track with histone mutation status at all.

Instead, the decisive variable was the tumor cell’s lineage state. Pediatric glioma cells oscillate among four transcriptional identities, resembling neural progenitor cells, astrocytes, oligodendrocyte precursors, or mesenchymal cells. Using single-sample gene set enrichment analysis, the researchers computed chemokine scores and lineage scores for every cell line and found a strong positive correlation between chemokine expression and the mesenchymal-like program, with a Pearson coefficient of 0.73 and a p-value of 6.5 times ten to the minus nine. Chemokine scores correlated negatively with both the neural progenitor-like and oligodendrocyte precursor-like scores and showed no significant relationship with the astrocyte-like state. Mesenchymal-like cell lines expressed significantly higher levels of CCL2, CCL5, and CCL7 than their counterparts. This suggests that the mesenchymal program, potentially driven by NF-kappaB and STAT3 signaling, is the engine of myeloid recruitment, and it hints at a self-reinforcing loop in which mesenchymal tumor cells summon macrophages that in turn stabilize the mesenchymal phenotype.

Single-cell RNA sequencing of eight DIPG patients, integrated with public datasets spanning H3K27M-mutant, G34R/V-mutant, and wildtype pediatric high-grade gliomas, then allowed the team to reconstruct cellular communication networks across more than twenty-two thousand cells. CellChat analysis revealed that tumor-associated macrophages were present in every histone subtype examined and were the sole recipients of several incoming signals, including TGF-beta, semaphorin-3, and, most intriguingly, the amyloid precursor protein signaling pathway transmitted through the CD74 receptor. Immunofluorescence staining of tumor sections confirmed that APP and CD74-expressing cells occupy spatial proximity within the tumor, consistent with a real ligand-receptor interaction occurring in the microenvironment. APP was broadly expressed across most cell populations, whereas CD74 was restricted to tumor-associated macrophages, defining a one-way channel of communication from tumor to immune cell.

The most consequential observation, however, was what was missing. APP expression was significantly reduced in DIPG tumor tissue compared with matched normal brain at both the RNA and protein levels, a result confirmed by western blotting and mirrored by decreased expression of the related family members APLP1 and APLP2. To understand what this loss means for macrophage behavior, the researchers treated THP-1-derived macrophages with recombinant human APP protein. The stimulation triggered a robust proinflammatory transformation: interferon-stimulated genes such as IFIT1 and IFIT2 were induced, inflammatory cytokines including IL1B, CCL2, and CXCL10 rose, and immunosuppressive markers such as CD163, CD206, and ARG2 were suppressed. Gene set enrichment analysis confirmed strong activation of interferon alpha, interferon gamma, and TNF alpha signaling via NF-kappaB, and multiplex cytokine assays showed time-dependent increases in secreted IFN-gamma, TNF-alpha, IL-1beta, and IL-6.

These functional data support a compelling hypothesis: when APP levels fall in the tumor, macrophages lose a signal that would otherwise push them toward an inflammatory, potentially anti-tumor state, and instead settle into the non-inflammatory, immunosuppressive phenotype that characterizes DIPG. The authors caution that the causal relationship remains to be established, and they note an apparent discrepancy with a recent glioblastoma study in which APP appeared to suppress macrophage phagocytosis via CD74, suggesting that context and the specific cellular readout matter. To lay groundwork for therapeutic intervention, the team went further, building three-dimensional structural models of membrane-bound APP and the CD74 trimer using I-TASSER-MTD, refining them in GROMACS, and performing protein-protein docking with HADDOCK. Membrane-restrained Gaussian network modeling then identified a mechanically rigid binding interface in which APP residues 19 through 24 engage a hydrophobic pocket in CD74 centered on residues 118 through 122.

That structurally defined interface offers an actionable target. Peptides engineered to engage the CD74 hydrophobic pocket could, in principle, mimic APP signaling and reprogram tumor-associated macrophages toward proinflammatory phenotypes with anti-tumor capacity, complementing emerging CAR-T cell therapies directed against GD2, B7-H3, and IL13-Ralpha2. The authors acknowledge important limitations: the sequencing work relied on post-mortem tissue from patients who had received varied treatments, the THP-1 model does not fully recapitulate the complexity of primary human macrophages, and the computational docking will require validation through site-directed mutagenesis and co-immunoprecipitation. Still, the study represents a substantial advance in understanding how lineage identity governs immune recruitment in pediatric high-grade glioma and how a protein famous in neurodegeneration may hold the key to thawing one of childhood cancer’s coldest tumors. Future studies using biopsy specimens, primary human systems, and syngeneic preclinical models will determine whether restoring APP-CD74 signaling can genuinely convert the immunosuppressive microenvironment of DIPG into one that fights back.

Subject of Research: Tumor-associated macrophage recruitment and the APP-CD74 signaling axis in pediatric high-grade glioma

Article Title: Integrated multi-omics identifies lineage-dependent myeloid cells recruitment and the APP-CD74 axis as an immunoregulatory target in pediatric high-grade glioma

Article References: Wang, Z., Kumar, A., Umaru, B., Iyer, A. M., Khan, K., Pang, H.-H., Fouladi, M., & Drissi, R. (2026). Integrated multi-omics identifies lineage-dependent myeloid cells recruitment and the APP-CD74 axis as an immunoregulatory target in pediatric high-grade glioma. Acta Neuropathologica, 152(1), Article 39. https://doi.org/10.1007/s00401-026-03089-0

Image Credits: AI Generated

DOI: 10.1007/s00401-026-03089-0

Keywords: diffuse intrinsic pontine glioma, pediatric high-grade glioma, tumor-associated macrophages, APP-CD74 axis, amyloid precursor protein, CD74, tumor microenvironment, single-cell RNA sequencing, mesenchymal-like lineage state, chemokines, immunotherapy, multi-omics